The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yes MD.J.M whats interesting with Remdesivir is that it has skipped the usual double blind P3 testing here and its the second time this has happened the first in the last big Ebola outbreak which possibly sets a precedent?
Anyways a vacine it will never be.
Its good to see such a promising portfolio albeit quite far down in the pipeline. Gives the company some depth.
This is quite unprecedented as Remdesivir hasn’t been trialled before and it’s safety profile is not known. It did get used for an Ebola outbreak but wasn’t as effective as other drugs used. Again no P3 trial in at the deep end. WHO used new protocols for its use.
Might this herald the beginning of a new approach?
How will that affect Imm? Safety profile assured!!
Lupuzor has already proven to be very effective with patients carrying a certain bio marker.
The next RNS hopefully coming soon regarding trial design might be a real eye opener.
Fingers crossed here for the Lupus sufferers.
May even speed up the process. IMO
Thanks for the post NoLupus.
Looks promising let’s hope The President doesn’t put his “midus touch” on it!!
I did notice this comment which at this stage seems fair;
“drawing any conclusions at this point is premature and scientifically unsound.”
Oooo yes Halfbutt im looking forward to a bit of news too. Not long now im thinking. Will bring a bit of volume and volitility with it, and the tin pot trader gang with their grand asperations for Imm he he!! Have a bit put by if I can keep it there!!
Valid points Seeingtom. The current share price reflects these uncertainties. When/if these points are worked out then the share price rise. As we have seen recently as there are few shares available, when/if an announcement arrives it will be difficult to jump on the rise. Risk and reward.
For sure Oranges.
Its my guess that he held too much power in the boardroom. Somebody may have used recent events to unseat him, although saying that the board have retained his presence. Im guessing the Americans dont want a deal they want the company? The potential here is huge in the near future. The USA market is ready now for an alternative to IV infusion. Im expecting things to move quickly from here. DYOR though!!
Holding tight.
For sure Oranges.
Its my guess that he held too much power in the boardroom. Somebody may have used recent events to unseat him, although saying that the board have retained his presence. Im guessing the Americans dont want a deal they want the company? The potential here is huge in the near future. The USA market is ready now for an alternative to IV infusion. Im expecting things to move quickly from here. DYOR though!!
Holding tight.